Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 12/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701125 | 0.91 | LMNA (0.66) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL16709546 | 0.89 | LMNA (0.56) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL14689242 | 0.89 | LMNA (0.63) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL14689726 | 0.89 | LMNA (0.54) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL14689385 | 0.88 | CNR2 (0.63) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL411822 | 0.83 | LMNA (1.00) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL14690146 | 0.82 | LMNA (0.53) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL19547484 | 0.80 | MAPT (0.77) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL14689805 | 0.79 | LMNA (0.64) | LMNAMAPTRECQLMEN1KMT2A | |
| SCHEMBL18925969 | 0.79 | MAPT (0.70) | LMNAMAPTRECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| EP-2925129-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-10-07 | — | — | EP | claimed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-07-18 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9902713-B2 | Neuroprotective compounds and use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-27 | — | — | US | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | NLN, GAP43, BDNF | LMNA 163/4885MAPT 42/4885RECQL 3493/4885 |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | LMNA 212/4885MAPT 141/4885RECQL 2782/4885 |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | LMNA 67/4885MAPT 122/4885RECQL 2999/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | LMNA 174/4885MAPT 136/4885RECQL 2885/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | LMNA 523/4885MAPT 142/4885RECQL 2553/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | LMNA 174/4885MAPT 136/4885RECQL 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.